REMARKS

Originally filed claims 1-65 were canceled and claims 66-132 were presented as new claims in correspondence from the Applicant to the Patent Office dated November 4, 2005. Certain claims within 66-132 are hereby amended or canceled, and claims 133-134 are hereby presented as new claims. Applicants believe that the claims have been clarified for more convenient examination. A substitute specification has been filed at the same time as the present amendment and under the same cover.

The support for these changes to the claims is provided below, with page and line numbers referring to the as-filed (not substitute) specification.

Claim 66 as currently amended claims a composition comprising at least one biocompatible polymer. This is supported by the specification, e.g., at page 23, line 18, which describes that the biocompatible polymer may be supplied in various prepared mixtures of two or more biocompatible polymers that are subsequently combined to form the biocompatible polymer component. Claim 66 also recites the biocompatible polymer to be for specific cellular or tissue uptake. This amendment is supported by the specification, e.g., at page 30, line 3, which describes that the specific cellular or tissue uptake can be achieved by polymer selection. Claim 66 as amended also claims a composition comprising a surfactant having an HLB value of less than about 6.0 units. This is supported by the specification, e.g., at page 16, line 22.

Claim 67 as currently amended claims bioactive components comprising macromolecules. Support for this amendment is found in the specification, e.g., at page 11, line 24.

Claim 71 as currently amended adds peptide nucleic acid as a macromolecule. Support for this claim is found at page 30, line 10.

Claim 76 as currently amended claims bioactive components comprising a chemotherapeutic agent. Support for this claim is found in the specification, e.g., at page 30, line 8.

Claim 78 as currently amended claims bioactive components comprising an inorganic agent. Support for this claim is found in the specification, e.g., at page 12, line 3.

Claims 80 and 81 are currently amended to restate the list of described bioactive components to be consistent with the originally filed claims.

Claims 83 - 85 as currently amended recite a biocompatible polymer comprising a molecule for cell or tissue specific targeting. This change is consistent with the changes described for claim 67.

Claim 86 is currently amended to claim the biocompatible polymer comprising a ligand that targets a receptor for tenascin. This claim was previously included in Claim 85.

Claim 89 is currently amended with respect to micellar concentration; support for this amendment is found in the specification, e.g., at page 21, line 16.

Claim 97 is currently amended to reflect the applicable changes in Claim 66 and the language in the specification, e.g., at page 24, line 20.

Claim 102 as currently amended claims various compositions of biocompatible polymers. Support for this claim is found in the specification, e.g., at page 24, line 16.

Claim 114 as currently amended claims methods of delivering medicaments to include device and pulmonary. Support for this claim is found in the specification, e.g., at page 30, line 1.

Claim 116 as currently amended essentially combines previously presented claims 116, 117, 120 and 121, and states the composition includes a biocompatible targeting component.

Claims 126 as currently amended is identical to claim 67 described above, with the exception of being directed to claim 116.

Claim 127 as currently amended claims the bioactive component comprising a small molecule. Support for delivery of small molecules is found in the specification, e.g., page 50, line 2.

Claims 133 and 134 are newly presented and claim the ligand of tenascin for cell-specific targeting of particles. Support for these claims are found in the specification, e.g., at page 49, line 9.

In the set of claims 66-132 submitted November 4, 2005, 10 claims were independent and 57 claims were dependent. In the amended claims herewith, 12 claims are independent and 47 claims are dependent. Applicants have attached a claim calculation sheet to confirm no additional filing fees are required.

Applicant believes that this amendment puts the application in better form for examination, which examination is earnestly sought.

In view of the foregoing, it is submitted that this application is in condition for allowance. Favorable consideration and prompt allowance of the application are respectfully requested.

The Examiner is invited to telephone the undersigned if the Examiner believes it would be useful to advance prosecution.

Respectfully submitted,

Curtis B. Herbert, Ph.D., Esq.

Registration No. 45,443

Customer No. 24113
Pafterson, Thuente, Skaar & Christensen, P.A.
4800 IDS Center
80 South 8th Street

Minneapolis, Minnesota 55402-2100

Telephone: (612) 349-3008